Douglas Moore, MD
Pulmonary Disease · Omaha, NENPI 1265696876
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $34,415 of the $39,710 with a category attached, or 86.7%. Boehringer Ingelheim accounts for 71.1% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2019 at $18,260 and has fallen 87.1% since, to $2,348 in 2025. Among pulmonary disease clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 179 payments — averaging $221.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$28K
- Genentech USA, Inc.$10K
- AstraZeneca$514
- Grifols USA, LLC$228
- Jazz Pharmaceuticals Inc.$157
- Electromed, Inc.$123
- plus $785 from 20 others
What the payments were for
- Consulting fees$1,2153%
- Speaking & faculty fees$34,41587%
- Travel & lodging$1280%
- Food & beverage$3,92610%
- Education$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 52 | $28,239 |
| Genentech USA, Inc. | 33 | $9,663 |
| AstraZeneca(2 entities) | 26 | $514 |
| Grifols USA, LLC | 10 | $228 |
| Jazz Pharmaceuticals Inc. | 3 | $157 |
| Electromed, Inc. | 10 | $123 |
| Philips North America LLC | 6 | $105 |
| Harmony Biosciences LLC | 5 | $99 |
| Insmed, Inc. | 4 | $79 |
| Sanofi | 4 | $69 |
| United Therapeutics Corporation | 3 | $65 |
| Merck | 2 | $50 |
| Johnson & Johnson | 3 | $45 |
| Axsome Therapeutics, Inc. | 3 | $44 |
| Regeneron Healthcare Solutions, Inc. | 3 | $41 |
| GSK | 2 | $26 |
| Bayer | 1 | $21 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $20 |
| Mallinckrodt Hospital Products Inc. | 1 | $18 |
| La Jolla Pharmaceutical Company | 1 | $16 |
| Amgen | 1 | $16 |
| Circassia Inc. | 1 | $15 |
| Verona Pharma, Inc. | 1 | $15 |
| Gilead | 1 | $15 |
| Actelion Pharmaceuticals US, Inc. | 1 | $13 |
| Melinta Therapeutics, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$39,710 in reported general payments places this provider in the 95th percentile of 81 pulmonary disease providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 47 | $730,670 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 57 | $47,047 |
| Pirfenidone | 26 | $42,815 |
| Breo ElliptaFluticasone/Vilanterol | 77 | $32,909 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $16,443 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 27 | $14,697 |
| SymbicortBudesonide/Formoterol Fumarate | 22 | $9,098 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $6,048 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 22 | $4,370 |
| Mycophenolate Mofetil | 28 | $1,868 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 50 | $1,601 |
| Ventolin HfaAlbuterol Sulfate | 11 | $593 |
| Prednisone | 60 | $289 |
| Montelukast Sodium | 48 | $211 |
| Gabapentin | 11 | $144 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Combivent Respimat | $28,239 | $736,71859 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $26 | $94,653161 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $514 | $25,54139 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 81 pulmonary disease providers in Nebraska.
Other pulmonary disease in Omaha
- Stephen RennardOmaha$50K
- Adam WellsOmaha$26K
- Zachary DepewOmaha$26K
- Michael SanleyOmaha$17K
- Adam HighleyOmaha$15K
- Carolina LandeenOmaha$14K
- Patrick MeyersOmaha$12K
- John DickinsonOmaha$8K
- Palvannanathan GanesanOmaha$8K
- Lee MorrowOmaha$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.